Navigation Links
ViroPharma Augments Senior Management
Date:1/3/2008

- Company Appoints Thomas Doyle Vice President, Strategic Initiatives and Promotes Peter Wolf to Vice President, General Counsel and Secretary of the

Board of Directors -

EXTON, Pa., Jan. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that effective, January 1, 2008, Thomas F. Doyle has been appointed as vice president, strategic initiatives and J. Peter Wolf has been promoted to vice president, general counsel and secretary of the Board of Directors.

Mr. Doyle will oversee strategic planning efforts at ViroPharma including expanding exclusivity of the current product portfolio, and assist in business development activities. He will also continue leading the efforts in ViroPharma's ongoing discussions with the U.S. Food & Drug Administration regarding the company's continuing efforts to assure the safety of patients afflicted by C. difficile infection. Prior to his appointment, Mr. Doyle served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.

"Tom has been a great leader for ViroPharma for well over a decade and during that time has helped navigate the company through times of both prosperity and difficulty," commented Michel de Rosen, ViroPharma's president and chief executive officer. "Tom continues to represent well the ViroPharma values of teamwork, people, quality and courage; he has great passion for ViroPharma and his integrity is second to none. I look forward to continuing to work closely with Tom in this critical new role for ViroPharma's future."

Mr. Wolf will be responsible for the oversight of ViroPharma's legal department and serve as corporate secretary. Mr. Wolf has been ViroPharma's Associate General Counsel since April 2004. Immediately prior to joining ViroPharma, Mr. Wolf was an attorney at Pepper Hamilton LLP. Mr. Wolf received his J.D. from George Washington National Law Center. Prior to attending George Washington, Mr. Wolf received his B.A. in International Relations from the University of Delaware.

"Since joining ViroPharma in 2004, Pete has demonstrated great teamwork, sound judgment and excellent customer focus," commented de Rosen. "He has a seemingly limitless capacity for work. We are very fortunate at ViroPharma to have a highly qualified individual such as Pete already in the organization to assume and expand the role of general counsel."

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
2. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma to Present at the UBS Global Life Sciences Conference
5. ViroPharma to Present at the Maxim Group First Annual Growth Conference
6. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
7. MSC Names Paul Bode as Senior Vice President, Ancillary Sales
8. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
9. Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing
10. Sunrise to Unveil New Residence for Seniors at Clayton on the Park
11. American Lung Association Offers Biodiesel Scholarship to Minnesota High School Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , ... benign bony lump located on the forehead usually attributed to a facial fracture. Their ... pain. Dr. Shah has discovered an approach that is minimally invasive. He is an ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... ... 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) launched today the ... education institutions in Hong Kong to support teaching, learning and research. It is also ... of facilities in Hong Kong. , With an area of 620 square metres ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the ... with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence with a ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... Providing ... not understand the estate planning process, or where to even begin. “Now more than ... if you are to properly protect yourself and your family,” said attorney Lisa Edgar ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 /PRNewswire/ ... ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen ... the signing of a three-year exclusive sales representation ... a dedicated sales team to introduce Imprimis, ophthalmic ... focused in 13 states in the U.S. Midwest. Precision ...
Breaking Medicine Technology: